Cypherpunk's Leap Therapeutics Announces Publication Of Phase 2 DeFianCe Sirexatamab Data In Clinical Cancer Research; Study Missed ITT PFS Primary Endpoint But Showed DKK1-High Benefit, Median OS Not Reached vs. 14.4 Months
Share
Why It Matters
A medicine company shared results from testing a cancer drug. The drug didn't work as well as hoped for most patients, but it worked better for a specific group, which gives scientists new clues to study.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.